For investors evaluating emerging medical technology companies, the competitive advantages behind a product can be as important as financial results. That was the focus of a recent Medsider interview with Dr. Sudhir Srivastava, founder, chairman and CEO of SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies. Dr. Srivastava discussed the company’s strategy to broaden access to robotic surgery through lower-cost technology, physician training and remote surgical capabilities.
Affordability and accessibility remain the company’s core priorities as it expands its surgical robotics platform globally. Artificial intelligence, automation, and new robotic platforms remain central to the company’s long-term product roadmap. The SSi Mantra system was designed to reduce the cost of robotic surgery while supporting multiple specialties, including cardiac surgery. The company has installed more than 200 robotic systems and completed more than 11,700 robotic procedures, including over 170 telesurgeries.
Telesurgery and teleproctoring are becoming important differentiators, allowing expert surgeons to support complex procedures remotely. This capability can help address the shortage of skilled robotic surgeons in underserved regions. SS Innovations is pursuing FDA and European regulatory approvals while expanding into additional international markets.
Rather than concentrating solely on competing with existing robotic surgery platforms, Dr. Srivastava described SS Innovations’ objective as expanding access to hospitals and patients that have historically been unable to adopt robotic surgery because of equipment costs and operating expenses. The company’s strategy focuses on providing a more affordable alternative without compromising on clinical outcomes.
For more details on the interview and the company’s strategic direction, readers can access the full terms of use and disclaimers on the InvestorBrandNetwork website. Forward-looking statements in this article involve risks and uncertainties, as detailed in the company’s filings with the SEC.
